Cracking the Code: How Massachusetts Built the Most Intentional Life Sciences Ecosystem in the World

Southern Catalyst: How Atlanta Is Building the Southeast’s Life Sciences Powerhouse

Episode Description: Atlanta is often overlooked in the life sciences conversation—but what if that's exactly the point? In this episode of scientifica sessions, we go inside the Atlanta ecosystem to unpack how a city built on public health leadership, world-class institutions, and deep clinical infrastructure is quietly assembling one of the most strategically compelling life sciences hubs in the United States. Atlanta isn't trying to be Boston or San Diego. It's building something distinctly its own: a scale-up hub rooted in the interplay of the CDC, Emory University, Georgia Tech, a massive and diverse patient population, the world's busiest airport, and a collaboration culture that most markets can't manufacture. We explore how Atlanta is: * Defining its identity as a scale-up hub through Georgia's first-ever life sciences roadmap * Attracting global companies like UCB to site U.S. manufacturing in the Southeast * Building bio-literacy through K-12 programs that have reached over 270,000 students statewide * Developing clinical infrastructure—including Children's Healthcare of Atlanta, home to more pediatric clinical trial beds than any U.S. children's hospital system * Navigating the capital gap through government funding, foundations, and a maturing local venture ecosystem The conversation also confronts the valley of death head-on—what it actually looks like when a company survives it through disciplined decision-making, capital efficiency, and the courage to move slowly when everything says move fast. What We Covered: * Why assets alone don't create a hub—and what the interplay looks like in Atlanta * How Atlanta's distributed micro-hub structure creates both opportunity and challenge * The real estate decisions that kill companies—and the discipline required to avoid them * Why Atlanta's quality of life and cost structure are becoming a structural competitive advantage * How Georgia's first life sciences roadmap is shaping the ecosystem's next decade Takeaway: Atlanta didn't stumble into this moment. It built toward it for twenty years. The decade of intentionality starts now. Connect with the guests 🔗 LinkedIn: Maria Thacker Goethe [https://www.linkedin.com/in/mariathacker/]; Steven Damon [https://www.linkedin.com/in/steven-damon-a1966a5/]; Justin Burns, Ph.D. [https://www.linkedin.com/in/jburns301/]; Andy Roberts [https://www.linkedin.com/in/andy-roberts-cresa-atl/] 📩 Connect with the show: podcast@kronosscientifica.com [podcast@kronosscientifica.com] Produced by Thread and Tensor [https://www.linkedin.com/company/thread-tensor/].

Cracking the Code: How Massachusetts Built the Most Intentional Life Sciences Ecosystem in the World

Episode Description: Massachusetts is often viewed as the epicenter of biotech—but what actually makes this ecosystem work? In this episode of scientifica sessions, we go inside the Commonwealth to unpack the deliberate strategy behind one of the most successful life sciences hubs in the world. Joined by leaders from the Massachusetts Life Sciences Center (MLSC) and founders building within the ecosystem, this conversation moves beyond Kendall Square to reveal a statewide model designed for scale, inclusion, and long-term impact. At the center of it all is MLSC—a quasi-public engine deploying capital, building infrastructure, and shaping policy to ensure innovation doesn’t just start in Massachusetts, but stays and grows there. We explore how Massachusetts has: * Built a true public-private partnership across government, academia, and industry * Used non-dilutive funding to de-risk early innovation and unlock venture capital * Created intentional pathways for underrepresented founders through programs like Mass Next Gen * Expanded beyond Boston to develop thriving clusters across the entire Commonwealth * Leveraged density—not just of capital, but of experience, mentorship, and talent—to accelerate company growth The conversation also dives into one of the most critical challenges in biotech—the “valley of death”—and how Massachusetts is actively building systems to help companies transition from early discovery to viable, revenue-generating businesses. What emerges is a blueprint: an ecosystem that listens, evolves, and invests with purpose—across talent, infrastructure, capital, and community. If you’re building, investing, or thinking about how to scale innovation in life sciences, this episode offers a rare look at what it takes to get it right. What We Covered: * The four pillars of a successful life sciences hub. * Why non-dilutive funding is more than capital—it’s protection and development. * How MLSC designs programs based on real ecosystem gaps. * The role of density in mentorship, talent, and commercialization. * Why the future of biotech ecosystems is statewide—not city-bound. Takeaway: Massachusetts didn’t become a global leader by chance—it built an intentional system to make innovation inevitable. Connect with the guests 🔗 LinkedIn: Tiffany Walther, PhD; [https://www.linkedin.com/in/tiffanymrich/] https://www.linkedin.com/in/kelley-dowd-ph-d-398705b8/Samantha Johnson; [https://www.linkedin.com/in/samantha-johnson-7001b413a/] https://www.linkedin.com/in/kelley-dowd-ph-d-398705b8/Minmin (Mimi) Yen, PhD, MPH; [https://www.linkedin.com/in/minmin-yen/]Asmi Chakraborty, PhD [https://www.linkedin.com/in/asmi-chakraborty-cancerbiology/]; [https://www.linkedin.com/in/kelley-dowd-ph-d-398705b8/]Ryan Mudawar [https://www.linkedin.com/in/ryan-mudawar/] 📩 Connect with the show: podcast@kronosscientifica.com Produced by Thread and Tensor [https://www.linkedin.com/company/thread-tensor/].

The Frontier Formula: Oklahoma's Blueprint for America's Next Life Sciences Hub

Episode Description What if the next great American life sciences hub isn’t on the coasts—but in the heartland? In this episode of scientifica sessions, we look beyond the usual biotech strongholds to explore Oklahoma’s emergence as a new life sciences contender. While Boston and San Francisco dominate the narrative, Oklahoma is quietly building a different model—one that blends energy-sector expertise, agricultural biotechnology, and targeted infrastructure investment to create a distinct innovation advantage. Host Tabari Baker is joined by Oklahoma life sciences leaders: * Carol Curtis, PhD * Nicholete Davis * Kelley Dowd, PhD * Madison Jackson * Patrick Lucy Together, they unpack what it really takes to build a life sciences ecosystem from the ground up. This isn’t a generic “emerging hub” story—it’s a candid look at convergent innovation, where energy capital fuels therapeutic development, and regional strengths shape a new path forward. In this episode, you’ll learn: * Why Oklahoma’s “late start” may actually be a competitive advantage. * How energy-industry capital and operational discipline are being repurposed for biotech. * The infrastructure gaps that could accelerate—or constrain—ecosystem growth. * What funding models are emerging before traditional venture capital arrives. * How Oklahoma is addressing talent development without an established biotech workforce. * The unique role of Native American healthcare systems in advancing innovation. Key segments include: * The Anatomy of a Hub: Foundational assets and authentic differentiators. * Capital and Commercialization: Creative funding approaches and early success stories. * Infrastructure and Place: Lab space, cost structure, and quality-of-life advantages. * Talent Flywheels: Workforce pipelines and entrepreneurial culture building. Whether you’re an entrepreneur deciding where to launch, an investor searching for untapped opportunity, or a life sciences leader tracking how innovation geography is shifting, this episode offers actionable insight into one of biotechnology’s most compelling frontier markets. Connect with the guests 🔗 LinkedIn: Kelley Dowd [https://www.linkedin.com/in/kelley-dowd-ph-d-398705b8/], [https://www.linkedin.com/in/dangoddard77/]Nicholete Davis [https://www.linkedin.com/in/nicholete-davis/], [https://www.linkedin.com/in/dangoddard77/]Patrick Lucy [https://www.linkedin.com/in/patricklucy/], [https://www.linkedin.com/in/dangoddard77/]Carol Curtis [https://www.linkedin.com/in/carol-curtis-phd/], [https://www.linkedin.com/in/dangoddard77/]Madison Jackson [https://www.linkedin.com/in/madisonljackson/] 📩 Connect with the show: podcast@kronosscientifica.com Produced by Thread and Tensor [https://www.linkedin.com/company/thread-tensor/].

From Concept to Capital: How Early-Stage Biotech Gets Funded with Dan Goddard

EPISODE DESCRIPTION In this episode of scientifica sessions, host Tabari Baker (Founder & CEO, kronos scientifica [https://www.kronosscientifica.com/]) sits down with Dan Goddard, Business Development Lead at CFGO [https://www.cfgo.net/], to explore one of the most critical—and misunderstood—journeys in life sciences: moving a company from concept to capital. Early-stage biotech lives at the intersection of breakthrough science, disciplined execution, and financial reality. When those elements align, companies build durable foundations that survive pivots, funding cycles, and market downturns. When they don’t, even exceptional science can stall. This conversation breaks down why that gap exists—and how founders can close it. Dan brings decades of experience across early-stage biotech, venture-backed scaling companies, finance, planning, and investor readiness. Together, Dan and Tabari unpack what investors are actually looking for, why planning matters even when it’s guaranteed to change, and how discipline—not hype—drives long-term success. In this episode, you’ll hear insights on: * Why great science is necessary—but not sufficient—for fundraising. * How to plan effectively when you know the plan will be wrong. * Common budgeting mistakes founders make (and why being “under budget” can be a red flag). * The importance of milestones, burn rate, and timing in a constrained funding environment. * Why fractional expertise (finance, legal, regulatory) is essential for early-stage companies. * Platform vs. asset strategies—and how AI is reshaping both. * Lessons from prior biotech downturns and why contractions often produce the strongest companies. * How founders should rethink fundraising as a partnership, not a transaction. * The conversation also dives into the human side of company building: decision fatigue, leadership vulnerability, early hiring challenges, and knowing when to ask for help. Dan shares hard-won lessons from working with dozens of companies—and why honest dialogue with investors often unlocks more value than a perfect pitch deck. The episode closes with a powerful takeaway for founders navigating investor conversations: If you want advice, ask for money. If you want money, ask for advice. If you’re building, advising, or investing in early-stage biotech—and trying to understand what it really takes to turn innovation into impact—this episode is your playbook. ---------------------------------------- If You Liked This Episode… Share it with your team and subscribe to scientifica sessions for unfiltered conversations with the leaders shaping biotech, pharma, and medtech. Connect with Dan Goddard 🔗 LinkedIn: Dan Goddard [https://www.linkedin.com/in/dangoddard77/] 📩 Connect with the show: podcast@kronosscientifica.com [podcast@kronosscientifica.com]

From Friction to Function: Fixing Collaboration with Patrina Pellett and Chase Wasson

EPISODE DESCRIPTION In this episode of scientifica sessions, host Tabari Baker (Founder & CEO, kronos scientifica) tackles one of the most persistent—and consequential—tensions in life sciences: the complicated relationship between Medical Affairs and Commercial. Too often it’s a “love–hate” dynamic fueled by shared stakeholders, unclear roles, conflicting metrics, and leadership misalignment. When it works, the field moves in lockstep. When it doesn’t, everyone feels it—especially HCPs. Tabari is joined by two guests who live this challenge from different angles: * Patrina Pellett, Co-CEO of MSL Mastery, who trains Medical Affairs teams on field excellence, communication, and cross-functional collaboration. * Chase Wasson, a commercial executive with ~17 years across pharma, diagnostics, and medtech, who has seen collaboration drive real wins—and watched it break down when strategy and process aren’t aligned. Together, they unpack the real root causes behind friction: “owning” the HCP relationship (and the turf wars it creates), the lack of role clarity during onboarding, and how leadership mindset trickles down into day-to-day behavior. Chase argues that when strategy is aligned from the top, process follows—making ownership conflicts far easier to resolve. Patrina adds a powerful insight: collaboration failures often mirror how leaders talk about (and model) cross-functional partnership. The conversation gets practical fast. You’ll hear actionable frameworks and behaviors that reduce conflict and build trust, including: * How to create clarity on “who does what” without diminishing either function * Why empathy matters—and how simply understanding your partner’s metrics changes everything * How Medical can avoid being perceived as the “no police” by shifting language from “No” to “How do we get to a shared solution?” * Why MSLs need stronger “soft skills” training (and why commercial teams often have an advantage here) * The underrated power of follow-up—and how missing it quietly erodes credibility and internal trust * How commercial partners can better “position” MSLs with customers by introducing their expertise clearly and confidently They also touch on the evolving landscape and why changing rules only increases the need for tighter alignment across Medical, Commercial, and Marketing. If you’ve ever said “that’s my KOL,” felt steamrolled by another function, or struggled to coordinate around the same HCPs—this episode is your playbook.  IF YOU LIKED THIS EPISODE… If this discussion resonated with you, share it with your organization—and subscribe to scientifica sessions. We deliver unfiltered conversations with the innovators pushing biotech, pharma, and medtech forward. ---------------------------------------- CONNECT WITH PATRINA AND CHASE 📧 patrina@mslmastery.com 📧 chase.wasson@gmail.com 🔗 LinkedIn: Patrina Pellet, PhD [https://www.linkedin.com/in/patrina/] & [https://www.linkedin.com/in/genomicsellingsolutions/]Chase Wasson [https://www.linkedin.com/in/winthedaywasson/] 📩 Connect with the show: podcast@kronosscientifica.com ---------------------------------------- MUSIC CREDITS 1. 0:07:06 - Transliminal 2. 00:15:46 - Crystalize 3. 00:35:21 - Panic at the Frisco Episode recorded on October 14, 2025.  All information shared is current as of the recording date.